Anti-slit diaphragm antibodies on kidney biopsy identify pediatric patients with steroid-resistant nephrotic syndrome responsive to second-line immunosuppressants
Podocytopathies represent a group of glomerular disorders associated with minimal changes (MC) or focal segmental glomerulosclerosis (FSGS) lesion patterns at biopsy and heterogeneous responses to steroids. Anti-nephrin antibodies were previously found in such patients, suggesting an autoimmune form of podocytopathy. High resolution confocal microscopy on kidney biopsies of a cohort of 128 pediatric patients revealed localization of IgG along the slit diaphragm in 30% of patients with MC and 25% of those with FSGS, but not in other lesion patterns. Anti-nephrin IgG ELISA assay in the serum and stimulated emission depletion microscopy of kidney biopsies showed IgG-nephrin co-localization only in 77.8% of cases. Similar observations were obtained in a cohort of 48 adult patients with MC or FSGS at kidney biopsy, where IgG-nephrin colocalization was only 44.4%, suggesting the existence of autoantibodies binding to other slit proteins. Patients with anti-slit antibodies showed nephrotic syndrome at onset in 94.4% of cases. Patients with primary steroid-resistance had anti-slit antibodies in 27%, while those with secondary steroid-resistance in 87.5% of cases, irrespective of the histopathological lesion pattern. Steroid-resistant patients with anti-slit antibodies responded to second-line immunosuppressants in 92.3% vs. only 20% of patients that were anti-slit negative. No patient with anti-slit antibodies developed kidney failure vs. 51.7% of those negative for antibodies (66.7% with a genetic cause and 41.2% with a non-genetic cause). Thus, the detection of anti-slit antibodies can identify patients with an autoimmune podocytopathy responsive to treatment with second-line immunosuppressants, irrespective of the histopathological lesion pattern at biopsy.
Authors
- Elisa Buti
- Andrea Angeletti (ORCID: https://orcid.org/0000-0002-6121-5326)
- Maria Elena Melica (ORCID: https://orcid.org/0000-0002-4599-4083)
- Letizia De Chiara (ORCID: https://orcid.org/0000-0002-8548-2031)
- Maurizio Bruschi (ORCID: https://orcid.org/0000-0001-6036-1500)
- Benedetta Mazzinghi (ORCID: https://orcid.org/0000-0003-2809-5622)
- Viviana Palazzo (ORCID: https://orcid.org/0000-0001-7800-8094)
- Giulia Antonelli (ORCID: https://orcid.org/0000-0002-2555-2130)
- Gian Marco Ghiggeri (ORCID: https://orcid.org/0000-0003-3659-9062)
- Luigi Cirillo (ORCID: https://orcid.org/0000-0002-0440-7356)
- Paola Romagnani (ORCID: https://orcid.org/0000-0002-1774-8088)
- Josep M. Cruzado (ORCID: https://orcid.org/0000-0003-1388-8558)
- Carolina Conte (ORCID: https://orcid.org/0000-0002-7679-2935)
- Elena Lazzeri (ORCID: https://orcid.org/0000-0002-9505-2115)
- Carmela Errichiello (ORCID: https://orcid.org/0009-0006-8803-5698)
- Samuela Landini (ORCID: https://orcid.org/0000-0001-7423-0325)
- Laura Lasagni (ORCID: https://orcid.org/0000-0001-6553-9160)
- Anna Julie Peired (ORCID: https://orcid.org/0000-0001-9732-1369)
- Francesca Becherucci (ORCID: https://orcid.org/0000-0002-1011-7291)
- Maria Lucia Angelotti (ORCID: https://orcid.org/0000-0003-3988-7852)
- Valentina Raglianti (ORCID: https://orcid.org/0000-0002-6610-3251)
- Marco Allinovi (ORCID: https://orcid.org/0000-0001-9949-3543)
- Fiammetta Ravaglia (ORCID: https://orcid.org/0000-0001-7121-2324)
- Hans‐Joachim Anders (ORCID: https://orcid.org/0000-0003-2434-2956)
- Anna Maria Buccoliero (ORCID: https://orcid.org/0000-0002-4993-0765)
- Anna Montero
Institutions
- Istituto Giannina Gaslini (IT)
- Bellvitge University Hospital (ES)
- Meyer Children's Hospital (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Hospital of Prato (IT)
- University of Florence (IT)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Kidney International
- Published
- 2024-10-03
- DOI
- https://doi.org/10.1016/j.kint.2024.09.006
- Citations
- 53
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 17.98
Funders
- Ministero della Salute
- Università degli Studi di Firenze
- Regione Toscana
- Horizon 2020 Framework Programme